A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient Treated with Guselkumab

Introduction: Psoriasis is a chronic inflammatory skin disease requiring long-term treatment. However, there are approximately 71 million individuals with chronic HCV infection worldwide. In psoriatic patients affected by chronic HCV infection, conventional systemic drugs may be frequently contraindicated, while data on biologics use are limited. Case Presentation: The case of a 48-year-old Caucasian man suffering from a severe form of plaque psoriasis and affected by a chronic-HCV-infection treated with guselkumab has been reported. Despite a huge improvement of the skin lesions (PASI reduced from 18 to 2), guselkumab was discontinued due to an HCV-infection reactivation after 3 months of treatment. Conclusion: To the best of our knowledge, this is the first case report of the use of guselkumab in an HCV psoriatic patient. Further studies are needed to evaluate the safety of guselkumab in chronic HCV patients.